04Feb/23
Dual-Target CAR-T Cell Therapy Is Driving Next Wave of Innovation in Immunotherapy
Chimeric antigen receptor (CAR) T cells have been remarkably successful in the treatment of relapsed hematologic malignancies, such as acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), and multiple myeloma (MM). CD19 andRead More…